Health Care & Life Sciences » Biotechnology | Argos Therapeutics Inc.

Argos Therapeutics Inc.

Argos Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$3.27
Market Cap
$905.19 K
Shares Outstanding
10.59 M
Public Float
9.27 M

Profile

Address
4233 Technology Drive
Durham North Carolina 27704
United States
Employees -
Website http://www.argostherapeutics.com
Updated 09/14/2018
Argos Therapeutics, Inc. is a biopharmaceutical company, which engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. Its product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Ralph Steinman on May 8, 1997 and is headquartered in Durham, NC.

Financials

View All
Created with Highcharts 5.0.14Argos Therapeutics Inc.Net Income. Fiscal year is January-December. All values USD Thousands.23 92123 92153 30553 30574 78874 78853 02853 02840 57740 57720132014201520162017020k40k60k80k
Created with Highcharts 5.0.14Argos Therapeutics Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.4 4214 4211 9741 9745185189459451 8991 8992013201420152016201701k2k3k4k5k

Hubert Birner
Chairman
Jeffrey D. Abbey
President, Chief Executive Officer & Director